News

Sharing, learning, networking, collaborating

eSight’s medical equipment enhances vision for individuals with over 20 distinct ocular disorders, frequently enabling users to attain 20/20 vision. The Consumer Electronics Show runs January 9-12 in Las Vegas.

The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19

According to OKYO Pharma, the first-in-human, randomized, double-masked, placebo-controlled trial of OK-101 “established a clear and informed path for further development in Phase 3 registration trials.”

The device is intended for use for LASIK vision correction surgery for myopia and myopic astigmatism.

Researchers found the administration of the neuropeptide α–melanocyte–stimulating hormone promotes corneal healing and restores normal eye function to an otherwise degenerating and diseased cornea by providing protection against cell death and promoting cell regeneration.

The company announced more advancements of its RASP modulator platform, including plans for ADX-629 and ADX-246.

This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.

Albert S Jun, MD, PhD, comes to UVA from the Johns Hopkins University School of Medicine.

Hawaiian Eye and Retina 2024 meetings will take place from January 13 to 19 at the Grand Wailea Maui, 3850 Wailea Alanui Drive, Wailea, HI.

The study will evaluate the safety and efficacy of fluocinolone acetonide intravitreal implant 0.18mg, (YUTIQ) in the treatment of chronic non-infectious uveitis and related intraocular inflammation.

The revision is in response to multiple recalls for eye drops and instances of consumer injury and death in 2023.

According to the company, Phase 3 startup activities are underway, and the clinical trial is expected to start in the first quarter of 2024.

A specialist in the field of ophthalmology and gene therapy, Dr Girach’s appointment enhances SpliceBio’s leadership team as it accelerates lead program targeting Stargardt disease towards clinical development.

The company is announcing 3 market access partnerships with PhilRx, Apollo Care, and PARx Solutions, expanding US availability of the solution.

According to a news release, the services will be provided for RetinalGeniX Technologies’ Institutional Review Board to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration.

All five MACs have now issued statements that the final LCDs will not go into effect on January 29, 2024. The MACs had identified certain procedures as investigational for glaucoma management in patients over the age of 18.

According to researchers, the strongest biomarker was achieved from a single bright flash of light to the right eye, with AI processing significantly reducing the test time.

Available information includes a new promotional toolkit for The Glaucoma Community, glaucoma patient testimonial, and medical expert interview videos.

DED incidence rates vary markedly depending on the ophthalmic practice.

Research can drive opportunities for patients with rare diseases

The company announced plans to enroll 320 volunteers in the study. Vezocolmitide is the first drug candidate based on PolyCol, Stuart Therapeutics' patented synthesized polypeptide collagen mimetic peptide platform.

Anchored matching-adjusted indirect comparison may aid decision-making

From FDA approvals to innovations in lens tech, 2023 was a big year in eye care.

A review of Opthalmology Times Europe's most important content from throughout the year

Catch up on a few of Modern Retina's top stories and ones you may have missed in 2023

Government focus on preventing blindness as well as rising elderly population are key drivers behind this growth.

A tailored treatment plan can help surgeons offer personalized care for patients.

A look back at some of the biggest stories in ophthalmology in 2023.

A genome topology map of human retina development lays the foundation for understanding diverse clinical phenotypes in simple and complex eye diseases.